MacKay Shields »

Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by MacKay Shields

Quarter-by-quarter ownership of Halozyme Therapeutics Inc Note 1.000 8/1 shares owned by MacKay Shields from 13F filings

Historical chart of MacKay Shields investment in Halozyme Therapeutics Inc Note 1.000 8/1

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics Inc Note 1.000 8/1 held by MacKay Shields consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics Inc Note 1.000 8/1 by MacKay Shields

Quarter filed Position value Share count Share price at filing
2024-09-30 $53M 45M 1.19
2024-06-30 $50M 45M 1.11
2024-03-31 $44M 45M 0.97
2023-12-31 $42M 45M 0.93
2023-09-30 $77M 83M 0.93

More positions owned by MacKay Shields

Lantheus Hldgs Note 2.625%12/1 (Principal)
Tetra Tech DBCV 2.250% 8/1 (Principal)
Transmedics Group Note 1.500% 6/0 (Principal)
Microchip Technology Note 0.125%11/1 (Principal)
Nrg Energy DBCV 2.750% 6/0 (Principal)
Zillow Group Note 1.375% 9/0 (Principal)
Post Hldgs Note 2.500% 8/1 (Principal)
Biomarin Pharmaceutical Note 1.250% 5/1 (Principal)
Ford Mtr Note 3/1 (Principal)
Integer Hldgs Corp Note 2.125% 2/1 (Principal)
Nice Note 9/1 (Principal)
Southwest Airls Note 1.250% 5/0 (Principal)
Patrick Inds Note 1.750%12/0 (Principal)
Lumentum Hldgs Note 0.500%12/1 (Principal)
Nextera Energy Unit 09/01/2025 (NEE.PR)

View all positions for MacKay Shields

Top funds holding Halozyme Therapeutics Inc Note 1.000 8/1

M&G
Citadel Advisors
MacKay Shields
Lazard Asset Management
Calamos Advisors
Polar Securities
BlackRock
Wolverine Asset Management
Ing Investment Management
Wells Fargo & Company
CNH Partners
State Street Corporation
BlackRock
Absolute Investment Advisers
Glazer Capital

View all funds holding Halozyme Therapeutics Inc Note 1.000 8/1